NCT00374296View on ClinicalTrials.gov

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Myelogenous Leukemia, AcuteMyelodysplastic Syndromes
Interventions
DRUG

MGCD0103

MGCD0103 administered orally three-times per week

Trial Locations (13)

43210

Ohio State University Medical Center - James Cancer Hospital, Columbus

44195

Cleveland Clinic, Cleveland

44718

Gabrail Cancer Center, Canton

64128

Veterans Affairs Medical Center, Kansas City

77030

MD Anderson Cancer Center, Houston

14642-0001

University of Rochester Medical Center, Rochester

L8N 3Z5

Hamilton Health Sciences - McMaster Hospital, Hamilton

M5G 2M6

UHN - Princess Margaret Hospital, Toronto

J4V 2H1

Hopital Charles Lemoyne, Greenfield Park

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

H3T 1E2

Sir Mortimer Davis-Jewish General Hospital, Montreal

J1H 5N4

Universite de Sherbrooke, Service d'hematologie, Sherbrooke

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00374296 - MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | Biotech Hunter | Biotech Hunter